Cellectis CLLS
NASDAQ CLLS
$1.38 +0.27 (+24.32%)
At close: Nov 11, 2026 · 4:00 PM EST

Cellectis (CLLS) Gains from Sales and Divestitures (2015)

Updated

Cellectis' Gains from Sales and Divestitures was $50,747 in Q4 2016, compared with -$40,556 a year earlier.

Analysis

Cellectis (CLLS) Gains from Sales and Divestitures (2015) Analysis & Trends

For FY2016, Gains from Sales and Divestitures at Cellectis came in at $64,209.

  • In earlier years, Gains from Sales and Divestitures was -$11,108 in FY2015 and -$31,903 in FY2014.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Cellectis 111.38 Mn -642.02 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2015 1,105.14
Mar 31, 2015 29,375.64
API Access

Cellectis Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=CLLS&period=max&api_key=YOUR_API_KEY